Biblio

Found 81 results
Author [ Title(Desc)] Type Year
Filters: Author is William H. Bisson  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
R. Nahta, Al-Mulla, F., Al-Temaimi, R., Amedei, A., Andrade-Vieira, R., Bay, S., Brown, D. G., Calaf, G. M., Castellino, R. C., Cohen-Solal, K. A., and Bisson, W. H., Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression, Carcinogenesis, vol. 36, pp. S2–S18, 2015.
A. C. Chlebowski, Garcia, G. R., La Du, J. K., Bisson, W. H., Truong, L., SL, M. Simonich, and Tanguay, R. L., Mechanistic investigations into the developmental toxicity of nitrated and heterocyclic PAHs., Toxicol Sci, 2017.
B. R Robey, Weisz, J., Kuemmerle, N., Salzberg, A. C., Berg, A., Brown, D. G., Kubik, L., Palorini, R., Al-Mulla, F., Al-Temaimi, R., and Bisson, W. H., Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?, Carcinogenesis, vol. 36, pp. S203–S231, 2015.
W. H. Bisson, Koch, D. C., O'Donnell, E. F., Khalil, S. M., Kerkvliet, N. I., Tanguay, R. L., Abagyan, R., and Kolluri, S. Kumar, Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands., J Med Chem, vol. 52, no. 18, pp. 5635-41, 2009.
W. H. Bisson, Koch, D. C., O'Donnell, E. F., Khalil, S. M., Kerkvliet, N. I., Tanguay, R. L., Abagyan, R., and Kolluri, S. Kumar, Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands, Journal of medicinal chemistry, vol. 52, pp. 5635–5641, 2009.
W. H. Bisson, Koch, D. C., Donnell, E. F. ’, Khalil, S. M., Kerkvliet, N. I., Tanguay, R. L., Abagyan, R., and Kolluri, S., Modeling of the Aryl Hydrocarbon Receptor (AhR) Ligand Binding Domain and Its Utility in Virtual Ligand Screening to Predict New AhR Ligands, Journal of Medicinal Chemistry, vol. 52, no. 18, pp. 5635 - 5641, 2009.
W. H. Bisson, Abagyan, R., and Cavasotto, C. N., Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations, Journal of Molecular Graphics and Modelling, vol. 27, no. 4, pp. 452 - 458, 2008.
C. V. Gerlach, Das, S. R., Volz, D. C., Bisson, W. H., Kolluri, S., and Tanguay, R., Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish, Aquatic Toxicology, vol. 154, pp. 71–79, 2014.
C. V. Gerlach, Das, S. R., Volz, D. C., Bisson, W. H., Kolluri, S., and Tanguay, R. L., Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish, Aquatic Toxicology, vol. 154, pp. 71 - 79, 2014.
C. V. Gerlach, Das, S. R., Volz, D. C., Bisson, W. H., Kolluri, S. K., and Tanguay, R. L., Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish., Aquat Toxicol, vol. 154, pp. 71-9, 2014.
S
S. Raduner, Bisson, W. H., Abagyan, R., Altmann, K. - H., and Gertsch, J., Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides, Journal of natural products, vol. 70, pp. 1010–1015, 2007.
J. D. Chavez, Wu, J., Bisson, W. H., and Maier, C. S., Site-specific proteomic analysis of lipoxidation adducts in cardiac mitochondria reveals chemical diversity of 2-alkenal adduction, Journal of proteomics, vol. 74, pp. 2417–2429, 2011.
A. Dehner, Planker, E., Gemmecker, G., Broxterman, Q. B., Bisson, W. H., Formaggio, F., Crisma, M., Toniolo, C., and Kessler, H., Solution Structure, Dimerization, and Dynamics of a Lipophilic $\alpha$/310-Helical, C$\alpha$-Methylated Peptide. Implications for Folding of Membrane Proteins, Journal of the American Chemical Society, vol. 123, pp. 6678–6686, 2001.
A. Perkins, Phillips, J. Lynne, Kerkvliet, N., Tanguay, R., Perdew, G., Kolluri, S., and Bisson, W. H., A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain, Biology, vol. 399, no. 4, pp. 645 - 669, 2014.
A. Perkins, Phillips, J. Lynne, Kerkvliet, N. I., Tanguay, R., Perdew, G. H., Kolluri, S., and Bisson, W. H., A structural switch between agonist and antagonist bound conformations for a ligand-optimized model of the human aryl hydrocarbon receptor ligand binding domain, Biology, vol. 3, pp. 645–669, 2014.
A. Perkins, Phillips, J. Lynne, Kerkvliet, N. I., Tanguay, R. L., Perdew, G. H., Kolluri, S. K., and Bisson, W. H., A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain., Biology (Basel), vol. 3, no. 4, pp. 645-69, 2014.
Y. Zhang, Yan, T., Sun, D., Xie, C., Zheng, Y., Zhang, L., Yagai, T., Krausz, K. W., Bisson, W. H., Yang, X., and Gonzalez, F. J., Structure-activity relationships of the main bioactive constituents of Euodia ruticarpa on aryl hydrocarbon receptor activation and bile acid homeostasis, Drug Metabolism and Disposition, p. dmd.117.080176, 2018.
I. A. Murray, Flaveny, C. A., Chiaro, C. R., Sharma, A. K., Tanos, R. S., Schroeder, J. C., Amin, S. G., Bisson, W. H., Kolluri, S., and Perdew, G. H., Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3′, 4′-dimethoxy-$\alpha$-naphthoflavone, Molecular pharmacology, vol. 79, pp. 508–519, 2011.
L. Mu, Drandarov, K., Bisson, W. H., Schibig, A., Wirz, C., P Schubiger, A., and Westera, G., Synthesis and binding studies of epibatidine analogues as ligands for the nicotinic acetylcholine receptors, European journal of medicinal chemistry, vol. 41, pp. 640–650, 2006.
S. Tardy, Orsato, A., Mologni, L., Bisson, W. H., Donadoni, C., Gambacorti-Passerini, C., Scapozza, L., Gueyrard, D., and Goekjian, P. G., Synthesis and biological evaluation of benzo [4, 5] imidazo [1, 2-c] pyrimidine and benzo [4, 5] imidazo [1, 2-a] pyrazine derivatives as anaplastic lymphoma kinase inhibitors, Bioorganic & medicinal chemistry, vol. 22, pp. 1303–1312, 2014.